TrialReader


Dual Algorithm Post Market Clinical Study

NCT03146013 — Completed, 100 participants, MP Biomedicals, LLC

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Evaluation of the MP Diagnostics HTLV Blot 2.4

RegistryNCT03146013
StatusCompleted
Study typeObservational
Enrollment100 (Actual)
SponsorMP Biomedicals, LLC (Industry); collaborators: MP Biomedicals Asia Pacific Pte. Ltd.
ConditionsHTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
InterventionsMP Diagnostics HTLV Blot 2.4 (Diagnostic test)
Datesstart 2017-03-01, primary completion 2017-05-31, completion 2017-05-31, first posted 2017-05-09, last updated 2017-06-12
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for HTLV-I Infections All trials for HTLV-II Infections All trials of MP Diagnostics HTLV Blot 2.4

-Summary

The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening assay (Avioq ELISA).

Expand all sections  ·  Collapse all

+Detailed description

This is a prospective study designed to assess the safety and effectiveness of a dual algorithm testing for HTLV I/II in blood donors. The study hypothesis is that blood donors testing repeat reactive (RR) on the first FDA licensed HTLV screening assay and non-reactive (NR) on a second FDA licensed screening assay will be confirmed as indeterminate or negative on the MP Diagnostics HTLV Blot 2.4.

+Arms and interventions

ArmTypeInterventionsDescription
HTLV Repeat Reactive (RR) / Non Reactive (NR)Diagnostic Test: MP Diagnostics HTLV Blot 2.4Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
  • MP Diagnostics HTLV Blot 2.4 (Diagnostic test), also known as HTLV I/II Western Blot Assay: HTLV I/II Confirmation and Differentiation

+Outcome measures

Primary outcomes

  • Assess the HTLV dual algorithm testing in blood donor facilities [3 months]: HTLV I/II confirmation of specimens testing RR on the first FDA licensed HTLV screening assay and non-reactive (NR) on a second FDA licensed HTLV screening assay.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. Male or female
2. Completion of a health history evaluation for routine donor screening
3. Provided a routine blood donation
4. Tests repeat reactive by the Abbott PRISM HTLV assay and non-reactive on the AVIOQ Elisa HTLV assay

Exclusion Criteria:

1. Unwilling or unable to provide informed consent to blood donation
2. Inadequate sample volume for testing
3. Unable to provide samples that meet the suitability requirements for testing

+Locations (1)

FacilityCityCountryStatus
American Red Cross - National Testing LaboratoryCharlotte, North CarolinaUnited States

+Publications

  • Miller L. Profile of the MP Diagnostics HTLV Blot 2.4 test: a supplemental assay for the confirmation and differentiation of antibodies to HTLV-1 and HTLV-2. Expert Rev Mol Diagn. 2016;16(2):135-45. doi: 10.1586/14737159.2016.1123622. Epub 2016 Jan 11. PMID 26589659

+Investigators

My Notes